Brief: Lineage Cell Therapeutics Inc - Reported Positive Results From Ongoing Scistar Study Of Opc1

Lineage Cell Therapeutics

15/11/2019 14:49

Lineage Cell Therapeutics Inc  LCTX.A :
    * LINEAGE CELL THERAPEUTICS PROVIDES UPDATE ON SCISTAR
CLINICAL
STUDY AND OPC1 SPINAL CORD INJURY PROGRAM
    * LINEAGE CELL THERAPEUTICS INC - REPORTED POSITIVE RESULTS
FROM
ONGOING SCISTAR STUDY OF OPC1
    * LINEAGE CELL THERAPEUTICS - OPC1 MANUFACTURING HAS BEEN
COMPLETELY TRANSFERRED TO CO'S CGMP MANUFACTURING FACILITY IN
ISRAEL
    * LINEAGE CELL THERAPEUTICS INC - INTENDS TO MEET WITH U.S.
FDA TO
DISCUSS FURTHER DEVELOPMENT OF OPC1 PROGRAM AROUND MIDDLE OF
2020
    * LINEAGE CELL - OVERALL SAFETY PROFILE OF OPC1 HAS REMAINED
EXCELLENT
    * LINEAGE CELL THERAPEUTICS - THERE HAVE BEEN NO UNEXPECTED
SERIOUS ADVERSE EVENTS RELATED TO OPC1 CELLS IN 21 SCISTAR STUDY
PATIENTS
    * LINEAGE CELL THERAPEUTICS INC - NO ADVERSE FINDINGS WERE
OBSERVED ON FOLLOW-UP MRI SCANS

Source text for Eikon:  ID:nBw995Tzsa 
Further company coverage:  LCTX.A